A phase 2 study of XL999 administered intravenously to subjects with metastatic renal cell carcinoma.
Latest Information Update: 30 Oct 2015
At a glance
- Drugs XL 999 (Primary)
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Symphony Evolution
- 23 Feb 2010 Actual end date (June 2007) added as reported by ClinicalTrials.gov.
- 16 Feb 2010 Actual patient number (11) added as reported by ClinicalTrials.gov.
- 16 Feb 2010 Symphony Evolution added as trial sponsor and trial affiliate as reported by ClinicalTrials.gov.